Paratek Pharmaceuticals (NASDAQ: PRTK)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-07 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.340 | -0.330 | 0.0100 | ||||
REV | 29.170M | 29.637M | 467.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Paratek Pharmaceuticals (NASDAQ: PRTK) through any online brokerage.
Other companies in Paratek Pharmaceuticals’s space includes: Satsuma Pharmaceuticals (NASDAQ:STSA), Harrow Health (NASDAQ:HROW), Anebulo Pharmaceuticals (NASDAQ:ANEB), Endo International (NASDAQ:ENDP) and Trevi Therapeutics (NASDAQ:TRVI).
The latest price target for Paratek Pharmaceuticals (NASDAQ: PRTK) was reported by HC Wainwright & Co. on Friday, May 6, 2022. The analyst firm set a price target for 20.00 expecting PRTK to rise to within 12 months (a possible 582.59% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Paratek Pharmaceuticals (NASDAQ: PRTK) is $2.93 last updated August 10, 2022, 8:00 PM UTC.
There are no upcoming dividends for Paratek Pharmaceuticals.
Paratek Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 7, 2022.
There is no upcoming split for Paratek Pharmaceuticals.
Paratek Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.